2010Chinese Heart JournalRequires access

Simvastatin inhibits RhoA translocation and Rho GTPase activity and prevents cardiac hypertrophy in chronic heart failure rabbit models

Jianping Song

Open publisher page 0 citations

Abstract

AIM:To investigate the effects of simvastatin on cardiac hypertrophy and the mechanism in chronic heart failure rabbit models.METHODS:Twenty four New Zealand rabbits were divided into four groups.Group I was designated the normal control group with sham operation.In the other three groups,aortic regurgitation and coarctation of ascending aorta were performed.Group II was designated the heart failure control group,Group III was the early treatment group [simvastatin 5 mg/(kg·day) postoperatively for 8 weeks] and Group IV represented the late treatment group [simvastatin 5 mg/(kg·day) 4 weeks postoperatively for 4 weeks].On weeks 0 and 8,echocardiographic evaluations were performed.At the eighth postoperative week,heart weight(HW),left ventricular weight(LVW),body weight(BW),heart weight/body weight ratio(HW/BW ratio),and left ventricular weight/body weight radio(LVW/BW ratio) were measured.RhoA expression in cardiomyocyte membrane was analyzed by Western blotting,and Rho GTPases activity was determined by GTP-binding assays.RESULTS:Compared with those in the heart failure control group,IVST,LVIDd,LVPwd,LVIDs,HW,LVW and HW/BW ratio were significantly lower but ejection fraction and fractional shortening were significantly higher in the early and late treatment groups.LVW/BW ratio in the early treatment group was significantly lower than in the heart failure control group.RhoA expression in cardiomyocyte membrane and GTPase activity in the heart failure control group were significantly higher than those in the normal control group but RhoA expression in cardiomyocyte membrane and GTPase activity in early and late treatment groups were significantly lower than in the heart failure control group.CONCLUSION:Simvastatin inhibits the translocation of RhoA from heart cell cytosolic to membrane and thus decreases the activity of Rho GTPase,possibly by reversing left ventricular remodeling and keeping cardiac functions of CHF rabbit model.

About this research paper

What this paper is about

AIM:To investigate the effects of simvastatin on cardiac hypertrophy and the mechanism in chronic heart failure rabbit models.METHODS:Twenty four New Zealand rabbits were divided into four groups.Group I was designated the normal control group with sham operation.In the other three groups,aortic regurgitation and coarctation of ascending aorta were performed.Group II was designated the heart failure control group,Group III was the early treatment group [simvastatin 5 mg/(kg·day) postoperatively for 8 weeks] and Group IV represented the late treatment group [simvastatin 5 mg/(kg·day) 4 weeks postoperatively for 4 weeks].On weeks 0 and 8,echocardiographic evaluations were performed.At the eighth postoperative week,heart weight(HW),left ventricular weight(LVW),body weight(BW),heart weight/body weight ratio(HW/BW ratio),and left ventricular weight/body weight radio(LVW/BW ratio) were measured.RhoA expression in cardiomyocyte membrane was analyzed by Western blotting,and Rho GTPases activity was determined by GTP-binding assays.RESULTS:Compared with those in the heart failure control group,IVST,LVIDd,LVPwd,LVIDs,HW,LVW and HW/BW ratio were significantly lower but ejection fraction and fractional shortening were significantly higher in the early and late treatment groups.LVW/BW ratio in the early treatment group was significantly lower than in the heart failure control group.RhoA expression in cardiomyocyte membrane and GTPase activity in the heart failure control group were significantly higher than those in the normal control group but RhoA expression in cardiomyocyte membrane and GTPase activity in early and late treatment groups were significantly lower than in the heart failure control group.CONCLUSION:Simvastatin inhibits the translocation of RhoA from heart cell cytosolic to membrane and thus decreases the activity of Rho GTPase,possibly by reversing left ventricular remodeling and keeping cardiac functions of CHF rabbit model.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

AIM:To investigate the effects of simvastatin on cardiac hypertrophy and the mechanism in chronic heart failure rabbit models.METHODS:Twenty four New Zealand rabbits were divided into four groups.Group I was designated the normal control group with sham operation.In the other three groups,aortic regurgitation and coarctation of ascending aorta were performed.Group II was designated the heart failure control group,Group III was the early treatment group [simvastatin 5 mg/(kg·day) postoperatively for 8 weeks] and Group IV represented the late treatment group [simvastatin 5 mg/(kg·day) 4 weeks postoperatively for 4 weeks].On weeks 0 and 8,echocardiographic evaluations were performed.At the eighth postoperative week,heart weight(HW),left ventricular weight(LVW),body weight(BW),heart weight/body weight ratio(HW/BW ratio),and left ventricular weight/body weight radio(LVW/BW ratio) were measured.RhoA expression in cardiomyocyte membrane was analyzed by Western blotting,and Rho GTPases activity was determined by GTP-binding assays.RESULTS:Compared with those in the heart failure control group,IVST,LVIDd,LVPwd,LVIDs,HW,LVW and HW/BW ratio were significantly lower but ejection fraction and fractional shortening were significantly higher in the early and late treatment groups.LVW/BW ratio in the early treatment group was significantly lower than in the heart failure control group.RhoA expression in cardiomyocyte membrane and GTPase activity in the heart failure control group were significantly higher than those in the normal control group but RhoA expression in cardiomyocyte membrane and GTPase activity in early and late treatment groups were significantly lower than in the heart failure control group.CONCLUSION:Simvastatin inhibits the translocation of RhoA from heart cell cytosolic to membrane and thus decreases the activity of Rho GTPase,possibly by reversing left ventricular remodeling and keeping cardiac functions of CHF rabbit model.

Key concepts: RHOA, Simvastatin, Internal medicine, Heart failure, Ejection fraction, Cardiology, Medicine, Endocrinology

Related papers

Back to paper searchBrowse research topicsOriginal source
Simvastatin inhibits RhoA translocation and Rho GTPase activity and prevents cardiac hypertrophy in chronic heart failure rabbit models — Research Paper | ScholarLens